Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

On May 15, 2013, we reiterated our recommendation for Allscripts Healthcare Solutions, Inc. (MDRX - Analyst Report) at Neutral based on the company’s first quarter results. 

Allscripts announced results for the reported quarter on May 9. While revenues and earnings missed the Zacks Consensus Estimates, bookings roughly stabilized on a sequential quarterly basis.

Allscripts should benefit from its position in the healthcare information technology space. It is believed that the small- and mid-sized ambulatory care market is well penetrated by Electronic Health Record (EHR). Allscripts has positioned itself by working in tandem with health systems that are providing EHR to their associate physicians. The company is seeing opportunities as doctors recognize that cheap products will not meet their requirements.  

Allscripts has engaged in synergistic tuck-in acquisitions. In the first quarter 2013, Allscripts acquired dbMotion and Follow My Health (formerly Jardogs). dbMotion is a competitive differentiator as it is a robust population health management vehicle. dbMotion also functions as a health information exchange center and analytics tool. Follow My Health has patient portal expertise. It is a part of the company’s community health effort and will serve as a stage for consumer interaction.

Allscripts has market share in both inpatient and ambulatory settings. Since incumbency is deemed to be the most significant competitive advantage, we believe the company will be a good performer in the long run.

Larger players, such as Allscripts and Cerner Corporation (CERN - Analyst Report), are expected to have an advantage over smaller competitors. However, the market is price sensitive particularly on the lower end.  Further, some competitors such as Cerner, have long ago developed unified and seamless products serving both inpatient and outpatient segments. Athenahealth, Inc. (ATHN - Analyst Report) is another competitor in a crowded field.

We currently have a Zacks Rank #4 (Sell) on the company. However, we are more positive about other medical information systems stocks such as Merge Healthcare Incorporated (MRGE - Analyst Report) which carries a Zacks Rank #2 (Buy) and is expected to do well. 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%